Predicting Outcomes in Breast Cancer

Video

Charles M. Perou, PhD, professor of genetics, pathology & laboratory medicine, UNC Lineberger Comprehensive Cancer Center, discusses the future of predicting outcomes in breast cancer.

Clinical Pearls

Charles M. Perou, PhD, professor of genetics, pathology & laboratory medicine, UNC Lineberger Comprehensive Cancer Center, discusses the future of predicting outcomes in breast cancer.

  • The utility of genomic tests for prognosis is well established and growing in use in breast cancer. Prediction is the next stage.
  • Results from the CALGB 40601 study demonstrate that tumor subtype and microenvironment is potentially predictive of pCR rate.
  • The best way to measure microenvironment remains to be seen.
Recent Videos
Related Content
Neoadjuvant TAR-200 Plus Cetrelimab Safe in Cisplatin-Ineligible MIBC

Neoadjuvant TAR-200 Plus Cetrelimab Safe in Cisplatin-Ineligible MIBC

Jordyn Sava
April 1st 2025
Article

Neal Shore, MD, FACS, discussed findings from the SunRISe-4 trial of TAR-200 and cetrelimab in muscle-invasive bladder cancer.

Read More

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Jordyn Sava;Aditya Bardia, MD, MPH
February 6th 2025
Podcast

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

Listen

Ocular Events With Mirvetuximab Show No Impact on QoL in Ovarian Cancer

Ocular Events With Mirvetuximab Show No Impact on QoL in Ovarian Cancer

Jordyn Sava
March 31st 2025
Article

Read More

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Jordyn Sava;Sanjay K. Juneja, MD
January 15th 2025
Podcast

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

Listen

Teclistamab, Daratumumab, Pomalidomide Is Feasible in Multiple Myeloma

Teclistamab, Daratumumab, Pomalidomide Is Feasible in Multiple Myeloma

Jordyn Sava
March 22nd 2025
Article

Anita D'Souza, MD, discussed the results from the MajesTEC-2 and TRIMM-2 trials in patients with multiple myeloma.

Read More

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Jonah Feldman
March 21st 2025
Article

Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.

Read More